Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT03396601

Organisation Name: NeuroRx, Inc.

Overal Status: Recruiting

Start Date: June 25, 2019

Last Update: October 30, 2020

Lead Sponsor: NeuroRx, Inc.

Brief Summary: NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation followed by oral NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for maintenance of stabilization from symptoms of depression and suicidal ideation. This study will test the hypothesis that that NRX-100 is superior to placebo in achieving rapid reduction in symptoms of depression and suicidal ideation in patients with Severe Bipolar Depression and Acute Suicidal Ideation or Behavior within 24 hours of administration.

Conditions:
  • Bipolar Depression
  • Suicidal Ideation


Total execution time in seconds: 0.17674708366394